Tags

Type your tag names separated by a space and hit enter

Serological monitoring of the response to chemotherapy in leprosy patients.
Int J Lepr Other Mycobact Dis. 1993 Mar; 61(1):35-43.IJ

Abstract

Sixty-five patients initially seropositive for IgM anti-phenolic glycolipid-I (PGL-I) antibodies were tested for antibody levels to PGL-I, lipoarabinomannan (LAM), and the 35-kDa protein of Mycobacterium leprae at regular intervals for up to 30 months following the commencement of multidrug therapy (MDT). There was a steady decline in IgM anti-PGL-I and anti-35-kDa antibody levels to a mean of 17% and 14%, respectively, of the starting level at 24 months. The development of type 1 and type 2 reactions or the presence of drug-resistant organisms in a small number of patients had no significant influence on the changes in antibody level. The rate of decline was similar in different disease categories, but a higher proportion of lepromatous patients remained seropositive at the end of 2 years of treatment than borderline tuberculoid patients. By contrast, the mean IgG anti-LAM antibody levels remained stable or increased. Again the occurrence of type 1 or type 2 reactions had no significant effect on antibody level over 2 years. Falls in the IgM anti-PGL-I antibody levels mirrored the falls in the bacterial index in individual patients and provide an additional parameter for monitoring the response to chemotherapy.

Authors+Show Affiliations

Roche PW
Mycobacterial Research Laboratory, Anandaban Leprosy Hospital, Kathmandu, Nepal.
Britton WJ
No affiliation info available
Failbus SS
No affiliation info available
Neupane KD
No affiliation info available
Theuvenet WJ
No affiliation info available

MeSH

AdolescentAdultAgedAntibodies, BacterialAntigens, BacterialChildDapsoneDrug Resistance, MicrobialDrug Therapy, CombinationFemaleGlycolipidsHumansImmunoglobulin GImmunoglobulin MLeprostatic AgentsLeprosy, BorderlineLeprosy, LepromatousLipopolysaccharidesMaleMiddle AgedMycobacterium lepraeRifampin

Pub Type(s)

Journal Article
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

8326179

Citation

Roche, P W., et al. "Serological Monitoring of the Response to Chemotherapy in Leprosy Patients." International Journal of Leprosy and Other Mycobacterial Diseases : Official Organ of the International Leprosy Association, vol. 61, no. 1, 1993, pp. 35-43.
Roche PW, Britton WJ, Failbus SS, et al. Serological monitoring of the response to chemotherapy in leprosy patients. Int J Lepr Other Mycobact Dis. 1993;61(1):35-43.
Roche, P. W., Britton, W. J., Failbus, S. S., Neupane, K. D., & Theuvenet, W. J. (1993). Serological monitoring of the response to chemotherapy in leprosy patients. International Journal of Leprosy and Other Mycobacterial Diseases : Official Organ of the International Leprosy Association, 61(1), 35-43.
Roche PW, et al. Serological Monitoring of the Response to Chemotherapy in Leprosy Patients. Int J Lepr Other Mycobact Dis. 1993;61(1):35-43. PubMed PMID: 8326179.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Serological monitoring of the response to chemotherapy in leprosy patients. AU - Roche,P W, AU - Britton,W J, AU - Failbus,S S, AU - Neupane,K D, AU - Theuvenet,W J, PY - 1993/3/1/pubmed PY - 1993/3/1/medline PY - 1993/3/1/entrez SP - 35 EP - 43 JF - International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association JO - Int J Lepr Other Mycobact Dis VL - 61 IS - 1 N2 - Sixty-five patients initially seropositive for IgM anti-phenolic glycolipid-I (PGL-I) antibodies were tested for antibody levels to PGL-I, lipoarabinomannan (LAM), and the 35-kDa protein of Mycobacterium leprae at regular intervals for up to 30 months following the commencement of multidrug therapy (MDT). There was a steady decline in IgM anti-PGL-I and anti-35-kDa antibody levels to a mean of 17% and 14%, respectively, of the starting level at 24 months. The development of type 1 and type 2 reactions or the presence of drug-resistant organisms in a small number of patients had no significant influence on the changes in antibody level. The rate of decline was similar in different disease categories, but a higher proportion of lepromatous patients remained seropositive at the end of 2 years of treatment than borderline tuberculoid patients. By contrast, the mean IgG anti-LAM antibody levels remained stable or increased. Again the occurrence of type 1 or type 2 reactions had no significant effect on antibody level over 2 years. Falls in the IgM anti-PGL-I antibody levels mirrored the falls in the bacterial index in individual patients and provide an additional parameter for monitoring the response to chemotherapy. SN - 0148-916X UR - https://www.unboundmedicine.com/medline/citation/8326179/Serological_monitoring_of_the_response_to_chemotherapy_in_leprosy_patients_ DB - PRIME DP - Unbound Medicine ER -